33. B-Cell Depleting Therapies and COVID-19
ACR on Air
00:00
The Impact of Medication on Immune Response to COVID, Influenza, and Other Vaccines
The NIAID ACV-01 trial is looking at additional dose responses, both in B-cell depleted people, but also people either on Method Rexy, or mycophanaly. There are a lot of people developing vaccines that are intranasally delivered, but most of these are live attenuated and we probably can't use for the immunosuppressed. The idea about mucosal immunity is the next thing I think about. And I think the third thing is going to be, you know, impact the Immunosuppression and durability of antibody responses.
Transcript
Play full episode
